FDA Approves Vyvgart for Myasthenia Gravis

By PPN News Staff

The FDA approved efgartigimod alfa-fcab (Vyvgart, argenx BV) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti–acetylcholine receptor (AChR) antibody.